科技导报 >

2025 , Vol. 43 >Issue 1: 96 - 101

DOI: https://doi.org/10.3981/j.issn.1000-7857.2025.01.00036

特色专题：2024年科技热点回眸

2024年免疫治疗研究热点回眸

  • 黄波
展开
  • 中国医学科学院基础医学研究所, 北京 100730

黄波，教授，研究方向为肿瘤免疫，电子信箱:

收稿日期: 2024-12-31

  网络出版日期: 2025-02-10

基金资助

国家自然科学基金项目(82388201)

版权

版权所有，未经授权，不得转载。
收起

Hotspots of immunotherapy in 2024

  • Bo HUANG
Expand
  • Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100730, China

Received date: 2024-12-31

  Online published: 2025-02-10

Copyright

All rights reserved. Unauthorized reproduction is prohibited.
Fold

摘要

2024年，免疫治疗领域取得了一系列重要进展，为疾病治疗提供了新的思路和方法。综述了肿瘤免疫治疗的新策略、嵌合抗原受体T细胞疗法（chimeric antigen receptor T-cell immunotherapy, CAR-T）治疗自身免疫性疾病的突破，以及肿瘤浸润性淋巴细胞（tumor infiltrating lymphocytes，TIL）和CAR-T在实体癌症治疗中的应用进展。在肿瘤免疫治疗方面，研究发现靶向肿瘤微环境中的T细胞代谢，如乳酸代谢和氨代谢，能够显著增强抗肿瘤免疫效应，为提高治疗效果提供了新的方向。此外，CAR-T在治疗自身免疫性疾病中展现出巨大潜力，通过基因编辑和优化CAR结构，实现了对难治性疾病的治疗突破，为自身免疫性疾病的治疗提供了新的解决方案。在实体癌症治疗中，TIL和CAR-T的优化策略，如代谢调控和个性化设计，进一步提升了其抗肿瘤活性，为实体瘤治疗开辟了新的道路。建议未来研究应加强对免疫代谢机制的深入探索，并结合纳米技术等新兴手段，以提高治疗的精准性和有效性。综上所述，免疫治疗在不断取得新的突破，为未来疾病治疗提供了更多可能性和新思路，有望为患者带来更好的治疗效果和生活质量。

关键词： 免疫代谢; 嵌合抗原受体T细胞疗法; 肿瘤浸润性淋巴细胞; 生物机械力

本文引用格式

黄波 . 2024年免疫治疗研究热点回眸[J]. 科技导报, 2025 , 43(1) : 96 -101 . DOI: 10.3981/j.issn.1000-7857.2025.01.00036

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序
1
Oliveira G , Wu C J . Dynamics and specificities of T cells in cancer immunotherapy[J]. Nature Reviews Cancer, 2023, 23: 295- 316.

DOI

2
Brudno J N , Maus M V , Hinrichs C S . CAR T cells and Tcell therapies for cancer[J]. JAMA, 2024, 332 (22): 1924.

DOI

3
Zhang H F , Liu J C , Yuan W , et al. Ammonia-induced lysosomal and mitochondrial damage causes cell death of effector CD8+ T cells[J]. Nature Cell Biology, 2024, 26: 1892- 1902.

DOI

4
Ding R , Yu X Y , Hu Z L , et al. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells[J]. Immunity, 2024, 57 (3): 528- 540.e6.

DOI

5
Ping Y , Shan J Q , Qin H M , et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis[J]. Immunity, 2024, 57 (9): 2122- 2139.e9..

DOI

6
Ma J W , Tang L , Tan Y Y , et al. Lithium carbonate revitalizes tumor-reactive CD8+ T cells by shunting lactic acid into mitochondria[J]. Nature Immunology, 2024, 25: 552- 561.

DOI

7
Jia D , Wang Q W , Qi Y D , et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer[J]. Cell, 2024, 187 (7): 1651- 1665.e21.

DOI

8
Xiao J , Wang S , Chen L L , et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages[J]. Immunity, 2024, 57 (5): 1087- 1104.e7.

DOI

9
Qiu Y J , Su Y P , Xie E M , et al. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity[J]. Cancer Cell, 2025, 43 (1): 103- 121.e8.

DOI

10
Ma M Y , Zhang Y L , Pu K Y , et al. Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity[J]. Chemical Society Reviews, 2025,

DOI

11
Wang X B , Wu X , Tan B H , et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis[J]. Cell, 2024, 187 (18): 4890- 4904.e9.

DOI

12
Jin G , Liu Y Y , Wang L X , et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice[J]. Nature Immunology, 2024, 25: 1059- 1072.

DOI

13
Klysz D D , Fowler C , Malipatlolla M , et al. Inosine induces stemness features in CAR-T cells and enhances potency[J]. Cancer Cell, 2024, 42 (2): 266- 282.e8.

DOI

14
Lacher S B , Dörr J , de Almeida G P , et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells[J]. Nature, 2024, 629: 417- 425.

DOI

15
Morotti M , Grimm A J , Hope H C , et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function[J]. Nature, 2024, 629 (8011): 426- 434.

DOI

16
Steffin D , Ghatwai N , Montalbano A , et al. Interleukin-15- armoured GPC3 CAR T cells for patients with solid cancers[J]. Nature, 2024,

DOI

17
Parkhurst M , Goff S L , Lowery F J , et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: Phase 2 trial interim results[J]. Nature Medicine, 2024, 30: 2586- 2595.

DOI

18
Piraner D I , Abedi M H , Duran Gonzalez M J , et al. Engineered receptors for soluble cellular communication and disease sensing[J]. Nature, 2024,

DOI

19
Xu X Y , Chen H T , Ren Z X , et al. Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity[J]. Immunity, 2024, 57 (12): 2755- 2771.e8.

DOI

20
Zhou Y B , Wang D H , Zhou L , et al. Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing[J]. Nature Communications, 2024, 15: 1405.

DOI

21
Zhang J J , Li J H , Hou Y Q , et al. Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor[J]. Cell, 2024, 187 (13): 3409- 3426.e24.

DOI

Options
文章导航

/

〈 〉

联系我们

  • 地址：北京市海淀区学院南路86号科技导报社　邮编：100081
  • 电话：010-62138113　传真：010-62138113
  • E-mail：kjdbbjb@cast.org.cn

    • 访问统计

      总访问量
      今日访问
      在线人数
    科技导报官方微信公众号
    京ICP备14028469号-1　
    版权所有 © 《科技导报》编辑部